Review: Antiplatelet Drugs: What Comes Next?

Antiplatelet drugs are important components in the management of atherothrombotic vascular disease. However, several limitations restrict the safety and efficacy of current antiplatelet therapy in clinical practice. Interpatient variability and resistance to aspirin and/or clopidogrel has spurred efforts for the development of novel agents. Indeed, several antiplatelet drugs are at various stages of evaluation; those at advanced stage of development are the focus of this review.

[1]  I. Pavord.  Asthma Phenotypes , 2012, Seminars in Respiratory and Critical Care Medicine.

[2]  A. Shuldiner,et al.  Genotyping: one piece of the puzzle to personalize antiplatelet therapy. , 2010, Journal of the American College of Cardiology.

[3]  V. Serebruany,et al.  Prasugrel as a potential cancer promoter: review of the unpublished data. , 2010, Archives of internal medicine.

[4]  A. Kastrati,et al.  Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. , 2010, European heart journal.

[5]  S. Ramsey,et al.  Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. , 2010, Archives of internal medicine.

[6]  J. Eikelboom,et al.  Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study , 2010, Circulation.

[7]  M. Keltai,et al.  Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study , 2010, The Lancet.

[8]  Irina Proskorovsky,et al.  Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction TRI , 2010, Circulation.

[9]  A. Shuldiner,et al.  The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c19*2 genotype: first experience in patients , 2010, Journal of thrombosis and haemostasis : JTH.

[10]  S. Steinhubl,et al.  Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist , 2010, Journal of clinical pharmacology.

[11]  Gregg W Stone,et al.  Platelet inhibition with cangrelor in patients undergoing PCI. , 2009, The New England journal of medicine.

[12]  A. Kastrati,et al.  Cangrelor - a champion lost in translation? , 2009, New England Journal of Medicine.

[13]  Deepak L. Bhatt,et al.  Intravenous platelet blockade with cangrelor during PCI. , 2009, The New England journal of medicine.

[14]  M. Banach,et al.  Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? , 2009, Medical science monitor : international medical journal of experimental and clinical research.

[15]  S. Husted,et al.  Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist , 2009, Cardiovascular therapeutics.

[16]  P. Armstrong,et al.  Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intra , 2009, American heart journal.

[17]  Mark J. Antonino,et al.  Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study , 2009, Circulation.

[18]  J. Mega,et al.  Abstract 2126: CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis , 2009 .

[19]  G. Montalescot,et al.  Prasugrel compared with high-dose clopidogrel in acute coronary syndrome , 2009, Thrombosis and Haemostasis.

[20]  M. Bousser,et al.  Effect of the Thromboxane Prostaglandin Receptor Antagonist Terutroban on Arterial Thrombogenesis after Repeated Administration in Patients Treated for the Prevention of Ischemic Stroke , 2009, Cerebrovascular Diseases.

[21]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[22]  F. Giordanetto,et al.  Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation , 2009, Journal of thrombosis and haemostasis : JTH.

[23]  J. Oestreich.  SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. , 2009, Current opinion in investigational drugs.

[24]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[25]  K. Kent,et al.  Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. , 2009, The American journal of cardiology.

[26]  I. Porto,et al.  Platelet P2Y12 receptor inhibition by thienopyridines: status and future , 2009, Expert opinion on investigational drugs.

[27]  P. Moayyedi,et al.  Is it safe to use a proton pump inhibitor with clopidogrel? , 2009, Polskie Archiwum Medycyny Wewnetrznej.

[28]  M. Movahed,et al.  ADP receptor-blocker thienopyridines: chemical structures, mode of action and clinical use. A review. , 2009, The Journal of invasive cardiology.

[29]  Deepak L. Bhatt,et al.  The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease , 2009, Thrombosis and Haemostasis.

[30]  M. Hennerici.  Rationale and Design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study , 2009, Cerebrovascular Diseases.

[31]  N. Clappers,et al.  Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects , 2009, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[32]  R. Peters,et al.  The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis. , 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[33]  K. Petersen.  Relevance of Metabolic Activation Pathways: The Example of Clopidogrel and Prasugrel , 2009, Arzneimittelforschung.

[34]  Á. Chamorro,et al.  The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study: Baseline Characteristics of the Population , 2009, Cerebrovascular Diseases.

[35]  S. Corrao,et al.  Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis. , 2009, Atherosclerosis.

[36]  A. Skene,et al.  Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.

[37]  J. Goudevenos,et al.  Aspirin resistance in cardiovascular disease: pathogenesis, diagnosis and clinical impact. , 2009, Current pharmaceutical design.

[38]  Peter C. Austin,et al.  A population-based study of the drug interaction between proton pump inhibitors and clopidogrel , 2009, Canadian Medical Association Journal.

[39]  K. Mahaffey,et al.  Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study , 2009, The Lancet.

[40]  P Michael Ho,et al.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. , 2009, JAMA.

[41]  E. Antman,et al.  Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial , 2009, The Lancet.

[42]  Pei-hua Wang,et al.  Increased Endothelial Nitric-Oxide Synthase Expression Reduces Hypertension and Hyperinsulinemia in Fructose-Treated Rats , 2009, Journal of Pharmacology and Experimental Therapeutics.

[43]  P. Steendijk,et al.  Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE*3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban)* , 2008, Critical care medicine.

[44]  E. Antman,et al.  Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial , 2008, European heart journal.

[45]  T. Brzozowski,et al.  Nitric oxide (NO)-releasing aspirin and (NO) donors in protection of gastric mucosa against stress. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[46]  K. Kim,et al.  The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance , 2008, Clinical pharmacology and therapeutics.

[47]  Sarah Battistone,et al.  2007 Guideline Update for Unstable Angina/Non–ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies , 2008, The Annals of pharmacotherapy.

[48]  M. Keltai,et al.  Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial , 2008, The Lancet.

[49]  K. Winters,et al.  Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel , 2008, Journal of clinical pharmacology.

[50]  Dominique Mottier,et al.  Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. , 2008, Journal of the American College of Cardiology.

[51]  K. Winters,et al.  The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration , 2008, Thrombosis and Haemostasis.

[52]  E. Antman,et al.  Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial , 2007, Circulation.

[53]  K. Winters,et al.  A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry , 2007, Thrombosis and Haemostasis.

[54]  G. Davı̀,et al.  Platelet activation and atherothrombosis. , 2007, The New England journal of medicine.

[55]  S. Iturria,et al.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.

[56]  J. Nishimura,et al.  Prevention of the Hypercontractile Response to Thrombin by Proteinase-Activated Receptor-1 Antagonist in Subarachnoid Hemorrhage , 2007, Stroke.

[57]  A. Siegbahn,et al.  Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. , 2007, European heart journal.

[58]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[59]  C. Cannon,et al.  Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. , 2007, Journal of the American College of Cardiology.

[60]  J. Björkman,et al.  Abstract 245: AZD6140 Inhibits Adenosine Uptake Into Erythrocytes and Enhances Coronary Blood Flow After Local Ischemia or Intracoronary Adenosine Infusion , 2007 .

[61]  W. Weaver,et al.  Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. , 2007, American heart journal.

[62]  G. Angelini,et al.  Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine (SIN-1). , 2007, The Journal of thoracic and cardiovascular surgery.

[63]  G. Vilahur,et al.  A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis , 2007, Thrombosis and Haemostasis.

[64]  K. Winters,et al.  Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. , 2007, The American journal of cardiology.

[65]  M. Burdick,et al.  Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. , 2007, Cancer research.

[66]  D. Mikhailidis,et al.  Platelets and vascular risk: an option for treatment. , 2007, Current pharmaceutical design.

[67]  D. Atar,et al.  Dyspnoea after antiplatelet agents: the AZD6140 controversy , 2007, International journal of clinical practice.

[68]  S. Coughlin,et al.  Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis , 2007, Proceedings of the National Academy of Sciences.

[69]  Wolfgang Koenig,et al.  Biomarkers of outcome from cardiovascular disease , 2006, Current opinion in critical care.

[70]  G. Stansby,et al.  Oral antiplatelet agents and bleeding risk in relation to major cardiovascular surgery. , 2006, Current drug safety.

[71]  V. Serebruany.  Dyspnoea after AZD6140: safety first? , 2006, European heart journal.

[72]  A. Siegbahn,et al.  Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. , 2006, European heart journal.

[73]  P. Sandset,et al.  Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. , 2006, European heart journal.

[74]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[75]  C. Derian,et al.  Blocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated Thrombosis , 2006, Circulation.

[76]  W. Weaver,et al.  Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. , 2006, American heart journal.

[77]  R. Eliakim,et al.  Minidose Aspirin and Gastrointestinal Bleeding—A Retrospective, Case–Control Study in Hospitalized Patients , 2005, Digestive Diseases and Sciences.

[78]  V. Fuster,et al.  Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study. , 2005, European heart journal.

[79]  S. Coughlin,et al.  Protease‐activated receptors in hemostasis, thrombosis and vascular biology , 2005, Journal of thrombosis and haemostasis : JTH.

[80]  J. Jakubowski,et al.  Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. , 2005, Seminars in thrombosis and hemostasis.

[81]  R. G. Humphries,et al.  Preclinical and Clinical Studies with Selective Reversible Direct P2Y12 Antagonists , 2005, Seminars in thrombosis and hemostasis.

[82]  F. Fauvel-Lafève,et al.  Platelet adhesion and signaling induced by the octapeptide primary binding sequence (KOGEOGPK) from type III collagen , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[83]  W. Vaughn,et al.  Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. , 2004, The Journal of thoracic and cardiovascular surgery.

[84]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[85]  P. Watkins,et al.  Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance , 2004, Circulation.

[86]  J. Herbert,et al.  Gi‐dependent and ‐independent mechanisms downstream of the P2Y12 ADP‐receptor , 2004, Journal of thrombosis and haemostasis : JTH.

[87]  M. Eichelbaum,et al.  Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine , 2004, Journal of Pharmacology and Experimental Therapeutics.

[88]  M. Arrebola,et al.  In Vitro Effects of Clopidogrel on the Platelet-Subendothelium Interaction, Platelet Thromboxane and Endothelial Prostacyclin Production, and Nitric Oxide Synthesis , 2004, Journal of cardiovascular pharmacology.

[89]  J. Wallace,et al.  Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[90]  J. Seki,et al.  Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. , 2003, European journal of pharmacology.

[91]  P. Barragan,et al.  Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator‐stimulated phosphoprotein phosphorylation , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[92]  J. Herbert,et al.  P2Y12, A New Platelet ADP Receptor, Target of Clopidogrel , 2003, Seminars in vascular medicine.

[93]  G. Pelle,et al.  Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. , 2003, Journal of the American College of Cardiology.

[94]  G. Geroulakos,et al.  The Effect of a Loading Dose (300 mg) of Clopidogrel on Platelet Function in Patients with Peripheral Arterial Disease , 2003, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[95]  S. Harder,et al.  Clopidogrel but not aspirin reduces P‐selectin expression and formation of platelet‐leukocyte aggregates in patients with atherosclerotic vascular disease * , 2003, Clinical pharmacology and therapeutics.

[96]  G. Gross,et al.  Comparison of Cardioprotective Efficacy of Two Thromboxane A2 Receptor Antagonists , 2003, Journal of cardiovascular pharmacology.

[97]  M. Bernatowicz,et al.  Peptide-derived protease-activated receptor-1 (PAR-1) antagonists. , 2003, Current medicinal chemistry. Cardiovascular and hematological agents.

[98]  M. D'Andrea,et al.  Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates , 2003, Journal of Pharmacology and Experimental Therapeutics.

[99]  P. Shaul.  Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis , 2003, The Journal of physiology.

[100]  G. Burnstock,et al.  Both the ADP receptors P2Y 1 and P2Y 12 , play a role in controlling shape change in human platelets , 2003, Platelets.

[101]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[102]  A. Nicolaides,et al.  S-18886 Servier. , 2002, Current opinion in investigational drugs.

[103]  R. Hongo,et al.  The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. , 2002, Journal of the American College of Cardiology.

[104]  R. Hongo,et al.  The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting , 2002 .

[105]  S. Harder,et al.  Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P‐selectin expression in a human ex vivo in vitro model , 2002, Clinical pharmacology and therapeutics.

[106]  G. Condorelli,et al.  Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[107]  R. Wunderink,et al.  Effect of clopidogrel on bleeding after coronary artery bypass surgery , 2001, Critical care medicine.

[108]  A. Lechi,et al.  NCX4016 (NO‐Aspirin) has multiple inhibitory effects in LPS‐stimulated human monocytes , 2001, British journal of pharmacology.

[109]  J. Goldstein,et al.  Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. , 2001, Biochemistry.

[110]  K. Schrör,et al.  Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel , 2001, Platelets.

[111]  C. A. Shaw,et al.  Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. , 2000, Biochemical and biophysical research communications.

[112]  V. Fuster,et al.  Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirin , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[113]  M. Bertrand,et al.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.

[114]  J. Wallace,et al.  Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[115]  J. Wallace,et al.  Nitric oxide in mucosal defense: a little goes a long way. , 2000, Gastroenterology.

[116]  G. FitzGerald,et al.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[117]  M. de Lorgeril,et al.  Ticlopidine increases nitric oxide generation in heart-transplant recipients: a possible novel property of ticlopidine. , 1998, Journal of cardiovascular pharmacology.

[118]  Huizinga Tw.  NCX-4016 NicOx SA. , 1998 .

[119]  L. Drouet,et al.  How does ticlopidine treatment lower plasma fibrinogen? , 1994, Thrombosis research.

[120]  J. F. Brown,et al.  Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric mucosal cells. , 1993, The American journal of physiology.

[121]  K. Honn,et al.  Platelets and cancer metastasis: A causal relationship? , 1992, Cancer and Metastasis Reviews.

[122]  A. Haeberli,et al.  Effects of the oral anticoagulant phenprocoumon on blood coagulation and thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood: role of dose and shear rate. , 1991, The Journal of laboratory and clinical medicine.

[123]  F. Kuzuya,et al.  Effects of Ticlopidine on Erythrocyte Aggregation in Thrombotic Disorders , 1991, Angiology.

[124]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[125]  H. Weiss,et al.  Effect of thromboxane receptor blockade on oxygen supply/consumption variables during reperfusion in the anesthetized dog. , 1990, The Journal of pharmacology and experimental therapeutics.

[126]  S Moncada,et al.  The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. , 1987, Biochemical and biophysical research communications.

[127]  S. Moncada,et al.  ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM , 1987, The Lancet.

[128]  S. Moncada,et al.  The anti‐aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide , 1987, British journal of pharmacology.

[129]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[130]  J. Brown,et al.  The assay of renin in single glomeruli in the normal rabbit and the appearance of the juxtaglomerular apparatus , 1965, The Journal of physiology.

[131]  N. Toma.  Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET study. , 2010, Maedica.

[132]  A. Dasgupta,et al.  Dual antiplatelet drug resistance in patients with acute coronary syndrome. , 2009, Indian heart journal.

[133]  K. Winters,et al.  A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. , 2007, American heart journal.

[134]  Eric J. Topol,et al.  Scientific and therapeutic advances in antiplatelet therapy , 2003, Nature Reviews Drug Discovery.

[135]  M. Flather,et al.  Antiplatelet therapy in peripheral arterial disease. Consensus statement. , 2003, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[136]  Caroline A Milton,et al.  For personal use. Only reproduce with permission from The Lancet Publishing Group. Late cardiopulmonary complication of ventriculo-atrial shunt , 2001 .

[137]  G. Kieffer,et al.  Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. , 1999, Seminars in thrombosis and hemostasis.

[138]  T. W. Huizinga.  NCX-4016 NicOx SA. , 1998, IDrugs : the investigational drugs journal.